Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Sheila K. Gujrathi M.D. | Executive Chairperson | 125k | -- | 1970 |
| Dr. Raju S. Mohan Ph.D. | Founder, CEO, President & Director | 905.29k | -- | 1958 |
| Dr. John M. Nuss Ph.D. | Chief Scientific Officer | 630.63k | -- | 1959 |
| Mr. Roy M. Gonzales CPA, M.B.A. | Senior VP of Finance and Principal Financial & Accounting Officer | -- | -- | 1976 |
| Mr. Matthew Richard Moore | Chief Operating Officer | -- | -- | 1973 |
| Dr. Mark S. Forman M.D., Ph.D. | Chief Medical Officer | -- | -- | 1966 |
| Ms. Snehal Naik Ph.D. | Senior VP of Clinical Development | -- | -- | -- |
| Ms. Kathy Ogilvie Ph.D. | Senior VP of Translational & Nonclinical Research | -- | -- | -- |
| Ms. Rosa Ferrao | Senior VP of Regulatory Affairs | -- | -- | -- |
Ventyx Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 79
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
February 27, 2025 at 9:05 PM UTC
Ventyx Biosciences, Inc. Earnings Date
Recent Events
November 13, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission